Oncology Drug Reference Sheet: Selinexor
Kristine B. LeFebvre, DNP, RN, NPD-BC, AOCN®
Voice
Description
After clinical trials demonstrated a 25% response rate in patients with multiple myeloma, selinexor (Xpovio®) received initial, accelerated U.S. Food and Drug Administration approval in 2019.
ONS Drug Education
Short summaries of newly approved oncology-related therapies or drugs with new indications.
View All Drug Education